Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC

Lung Cancer

Volumn 60, Issue 3, 2008, Pages 408-415

  Muley, Thomas ^a   Fetz, Timea Helene ^a   Dienemann, Hendrik ^a   Hoffmann, Hans ^a   Herth, Felix J F ^a   Meister, Michael ^a   Ebert, Werner ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CEA; CYFRA 21 1; Early stage; NSCLC; Prognosis; Tumor marker; Tumor volume

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GEOMETRY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 44249116641     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.10.026     Document Type: Article

References (35)

1. In: Manegold (Ed). Non-small cell lung cancer treatment. 1st ed. (2007), Uni-Med Science Verlag Bremen, Germany
2. Hotta K., Fujiwara Y., Kiura K., Takigawa N., Tabata M., Ueoka H., et al. Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thorac Oncol 2 (2007) 402-407
3. Pfannschmidt J., Muley T., Bulzebruck H., Hoffmann H., and Dienemann H. Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients. Lung Cancer 55 (2007) 371-377
4. Koike T., Tsuchiya R., Goya T., Sohara Y., and Miyaoka E. Prognostic factors in 3315 completely resected cases of clinical stage I non-small cell lung cancer in Japan. J Thorac Oncol 2 (2007) 408-413
5. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589-2597
6. Horn L., Sandler A.B., Putnam J.B., and Johnson D.H. The rational for adjuvant chemotherapy in stage I non-small cell lung cancer. J Thorac Oncol 2 (2007) 377-383
7. Brundage M.D., Davies D., and Mackillop M.B. Prognostic factors in non-small cell lung cancer-a decade of progress. Chest 122 (2002) 1037-1057
8. Mountain C.F. Revisions in the international item for staging lung cancer. Chest 111 (1997) 1710-1717
9. Suzuki K., Nagai K., Yoshida J., Moriyama E., Nishimura M., Takahashi K., et al. Prognostic factors in clinical stage I non-small cell lung cancer. Ann Thorac Surg 67 (1999) 927-932
10. Pujol J.L., Molinier O., Ebert W., Daurès J.P., Barlesi F., Buccheri G., et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 90 (2004) 2097-2105
11. Muley T., Dienemann H., and Ebert W. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC. Anticancer Res 23 (2003) 4085-4094
12. Reinmuth N., Brandt B., Semik M., Kunze W.-P., Achatzky R., Scheld H.H., et al. Prognostic impact of CYFRA 21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 36 (2002) 265-270
13. Kulpa J., Wojcik E., Reinfuss M., and Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 48 (2002) 1931-1937
14. Nisman B., Amir G., Lafair J., Heching N., Lyass O., Peretz T., et al. Prognostic value of CYFRA 21-1 TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res 19 (1999) 3549-3552
15. Muley T., Dienemann H., and Ebert W. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Anticancer Res 24 (2004) 1953-1956
16. Abel U., Berger S., and Wiebelt H. Critlevel. An exploratory procedure for the evaluation of quantitative prognostic factors. Methods Inf Med 23 (1984) 154-156
17. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
18. Cox D.R. Regression models and life tables (with discussion). J R Stat Soc 34 (1972) 187-220
19. Bhattacharjee A., Richards W.G., Staunton J., Li C., Monti S., Vasa P., et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci 98 (2001) 13790-13795
20. Beer D.G., Kardia S.L., Huang C.C., Giordano T.J., Levin A.M., Misek D.E., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8 (2002) 816-824
21. Kikuchi T., Daigo Y., Katagiri T., Tsunoda T., Okada K., Kakiuchi S., et al. Expression profiles of non-small cell cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 22 (2003) 2192-2205
22. Meyerson M., and Carbone D. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clin Oncol 23 (2005) 3219-3226
23. Larsen J.E., Pavay S.J., Passmore L.H., Bowman R.V., Hayward N.K., and Fong K.M. Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res 13 (2007) 2946-2954
24. Heighway J., Knapp T., Boyce L., Brennand S., Field J.K., Betticher D.C., et al. Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 21 (2002) 7749-7763
25. Tomida S., Koshikawa K., Yatabe Y., Harano T., Ogura N., Mitsudomi T., et al. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene 23 (2004) 5360-5370
26. Ramaswamy S., Ross K.N., Lander E.S., and Golub T.R. A moleculare signature of metastasis in primary solid tumors. Nat Genet 33 (2003) 49-53
27. Niklinski J., Burzykowski T., Niklinska W., Laudanski J., Chyczewski L., Rapellino M., et al. Preoperative CYFRA 21-1 level as a prognostic indicator in resected non-small cell lung cancer. Eur Resp J 12 (1998) 1424-1428
28. Pujol J.-L., Boher J.-M., Grenier J., and Quantin X. CYFRA 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 31 (2001) 221-231
29. Sawabata N., Otha M., Takeda S.I., Hirano H., Okumura Y., Asada H., et al. Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer. Ann Thorac Surg 74 (2002) 174-179
30. Carbone E., Asamura H., Takei H., Kondo H., Suzuki K., Miyaoka E., et al. T2 tumors larger than five centimeters in diameter can be upgraded to T3 in non-small cell lung cancer. J Thorac Cardiovasc Surg 122 (2001) 907-912
31. Lopez-Encuentra A., Duque-Medina J.L., Rami-Porta R., de la Camara A.G., and Ferrando P. Staging in lung cancer: is 3 cm a prognostic threshold in pathologic stage I non-small cell lung cancer? A multicenter study of 1020 patients. Chest 121 (2002) 1515-1520
32. Jefferson M.F., Pendleton N., Faragher E.B., Dixon G.R., Myskow M.W., and Horan M.A. Tumor volume as a predictor of survival after resection of non-small-cell lung cancer (NSCLC). Br J Cancer 74 (1996) 456-459
33. Dunhill M.S., and Gatter K.C. Cellular heterogeneity in lung cancer. Histopathology 10 (1986) 461-475
34. Müller K.M., and Wiethege T. Pathology, classification, and staging of lung tumors. Radiologe 44 (2004) 415-426
35. Dohmoto K., Hojo S., Fujita J., Ueda Y., Bandoh S., Yamaji Y., et al. Mechanisms of the release of CYFRA21-1 in human lung cancer cell lines. Lung Cancer 30 (2000) 55-63